
Congressmen Unveil Whistleblower Bill To Crack Down on Prediction Market Insider Trading
By JOSEPH CURL
|The lone senator to vote against a user fee program three time is expected to control its renewal.

With Democrats taking firm control of Congress, Big Pharma’s biggest critic is about to take over a Senate committee that has a big say in what the Food and Drug Administration spends on drug reviews.

By JOSEPH CURL
|
By DAVID JONES
|
By GEORGE WILLIS
|
By JOSEPH CURL
|
By A.R. HOFFMAN
|
By DONALD KIRK
|
By A.R. HOFFMAN
|
By HOLLIE McKAY
|With Democrats taking firm control of Congress, Big Pharma’s biggest critic is about to take over a Senate committee that has a big say in what the Food and Drug Administration spends on drug reviews.
Already have a subscription? Sign in to continue reading
Cancel anytime
By continuing you agree to our Privacy Policy and Terms of Service.
Cancel anytime